343 related articles for article (PubMed ID: 32816355)
1. Immunogenic chemotherapy in two mouse colon cancer models.
Taniura T; Iida Y; Kotani H; Ishitobi K; Tajima Y; Harada M
Cancer Sci; 2020 Oct; 111(10):3527-3539. PubMed ID: 32816355
[TBL] [Abstract][Full Text] [Related]
2. A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice.
Ishitobi K; Kotani H; Iida Y; Taniura T; Notsu Y; Tajima Y; Harada M
Int Immunopharmacol; 2022 Dec; 113(Pt A):109423. PubMed ID: 36461608
[TBL] [Abstract][Full Text] [Related]
3. Modulatory effects of supplementation of Lentinula edodes mycelia extract and l-arginine on the therapeutic efficacy of immunogenic chemotherapy in colon cancer-bearing mice.
Taniura T; Ishitobi K; Hidaka M; Harada M
Microbiol Immunol; 2024 Jan; 68(1):15-22. PubMed ID: 37964433
[TBL] [Abstract][Full Text] [Related]
4. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
5. Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy.
Satoh Y; Kotani H; Iida Y; Taniura T; Notsu Y; Harada M
Cancer Sci; 2020 Jul; 111(7):2248-2258. PubMed ID: 32426941
[TBL] [Abstract][Full Text] [Related]
6. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.
Iida Y; Harashima N; Motoshima T; Komohara Y; Eto M; Harada M
Cancer Sci; 2017 Oct; 108(10):1974-1984. PubMed ID: 28787548
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.
Kadhim S; Penney C; Lagraoui M; Heibein J; Attardo G; Zacharie B; Connolly T; Gagnon L
Int J Immunopharmacol; 2000 Sep; 22(9):659-71. PubMed ID: 10884587
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
9. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
Nigam A; Yacavone RF; Zahurak ML; Johns CM; Pardoll DM; Piantadosi S; Levitsky HI; Nelson WG
Int J Oncol; 1998 Jan; 12(1):161-70. PubMed ID: 9454900
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
12. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
Lin H; Wu Y; Chen J; Huang S; Wang Y
Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
[TBL] [Abstract][Full Text] [Related]
13. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
Tongu M; Harashima N; Tamada K; Chen L; Harada M
Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339
[TBL] [Abstract][Full Text] [Related]
14. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous inoculation position affects the immune environment in CT26 carcinomas.
Fu X; Yang Y; Xie J; Pan X; Yang X; Du Z; Hao E
Biochem Biophys Res Commun; 2019 Apr; 512(2):244-249. PubMed ID: 30879760
[TBL] [Abstract][Full Text] [Related]
16. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
[TBL] [Abstract][Full Text] [Related]
17. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
Gou HF; Huang J; Shi HS; Chen XC; Wang YS
PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice.
Xu L; Cai P; Li X; Wu X; Gao J; Liu W; Yang J; Xu Q; Guo W; Gu Y
Toxicol Appl Pharmacol; 2021 Oct; 428():115672. PubMed ID: 34391754
[TBL] [Abstract][Full Text] [Related]
19. Changes in T lymphocyte subsets in mice with CT26 colon tumors after treatment with donor lymphocyte infusion.
Jiang T; Piao D; Zhu A; Jiang H
Tumour Biol; 2014 Jun; 35(6):5599-605. PubMed ID: 24659423
[TBL] [Abstract][Full Text] [Related]
20. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
